• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物诱导的硬皮病样病变。

Drug-induced scleroderma-like lesion.

机构信息

Department of Molecular Pathology of Skin, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.

出版信息

Allergol Int. 2022 Apr;71(2):163-168. doi: 10.1016/j.alit.2021.08.005. Epub 2021 Aug 28.

DOI:10.1016/j.alit.2021.08.005
PMID:34465533
Abstract

Drug-induced scleroderma-like lesion is a condition in which administration of a drug induces skin sclerotic lesions similar to systemic sclerosis or morphea. The clinical manifestations of drug-induced scleroderma-like lesion can be divided into two types: scleroderma-like lesions and morphea-like plaques. A wide variety of drugs can cause drug-induced scleroderma-like lesion. Bleomycin, -tryptophan, vinyl chloride, and phytonadione (vitamin K) have been reported, but in recent years, cases due to chemotherapeutic agents, such as taxane-based agents, gemcitabine, and tegafur-uracil, and immune checkpoint inhibitors have increased. Drug-induced scleroderma-like lesion differs from systemic sclerosis in that it does not include Raynaud's phenomenon, nail-fold capillary abnormality, organ involvement, such as reflux esophagitis, interstitial pneumonia, renal crisis, or anti-nuclear Abs. On the other hand, there are reports of cases in which Raynaud's phenomenon, positive conversion of anti-nuclear Abs, and development of skin sclerosis from the fingers developed after initiation of the drug. Whether the skin sclerosis improves after discontinuation of the drug depends on the patient. In patients with severe skin sclerosis, functional impairment, such as flexion contracture of the fingers, may occur, and systemic therapy, such as steroids, may be necessary. When treating patients with skin sclerosis, it is important to keep in mind the possibility that the sclerotic lesion may be induced by a drug.

摘要

药物诱导的硬皮病样病变是一种药物引起的皮肤硬化性病变类似于系统性硬皮病或硬斑病的情况。药物诱导的硬皮病样病变的临床表现可分为两种类型:硬皮病样病变和硬斑病样斑块。多种药物可引起药物诱导的硬皮病样病变。已报道博来霉素、色氨酸、氯乙烯和叶绿醌(维生素 K),但近年来,由于化疗药物,如紫杉烷类药物、吉西他滨和替加氟-尿嘧啶,以及免疫检查点抑制剂,导致的病例有所增加。药物诱导的硬皮病样病变与系统性硬皮病不同,它不包括雷诺现象、甲襞毛细血管异常、反流性食管炎、间质性肺炎、肾危象或抗核抗体等器官受累。另一方面,有报道称,在开始使用药物后,出现雷诺现象、抗核抗体阳性转换和手指皮肤硬化的病例。皮肤硬化是否在停药后改善取决于患者。在皮肤严重硬化的患者中,可能会出现手指弯曲挛缩等功能障碍,可能需要全身性治疗,如皮质类固醇。在治疗皮肤硬化症患者时,重要的是要记住皮肤病变可能是由药物引起的可能性。

相似文献

1
Drug-induced scleroderma-like lesion.药物诱导的硬皮病样病变。
Allergol Int. 2022 Apr;71(2):163-168. doi: 10.1016/j.alit.2021.08.005. Epub 2021 Aug 28.
2
Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma.局限性硬皮病患者的毛细血管异常、雷诺现象和系统性硬化症。
Arch Dermatol. 1992 May;128(5):630-2.
3
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.硬皮病和硬皮病样疾病的皮肤表现:全面综述。
Clin Rev Allergy Immunol. 2017 Dec;53(3):306-336. doi: 10.1007/s12016-017-8625-4.
4
[How to recognize scleroderma].[如何识别硬皮病]
Rev Prat. 2002 Nov 1;52(17):1884-90.
5
Cutaneous and subcutaneous inflammatory sclerosis syndromes.皮肤和皮下炎性硬化综合征
Arch Dermatol. 1982 Nov;118(11):886-90.
6
Localized and systemic scleroderma.局限性和系统性硬皮病。
Semin Cutan Med Surg. 2001 Mar;20(1):27-37. doi: 10.1053/sder.2001.23093.
7
Skin capillary abnormalities as indicators of organ involvement in scleroderma (systemic sclerosis), Raynaud's syndrome and dermatomyositis.皮肤毛细血管异常作为硬皮病(系统性硬化症)、雷诺综合征和皮肌炎中器官受累的指标。
Am J Med. 1976 Dec;61(6):862-70. doi: 10.1016/0002-9343(76)90410-1.
8
[Capillary microscopy of the nail fold in Raynaud's phenomenon. Use in the early diagnosis of scleroderma].[雷诺现象中甲襞的毛细血管显微镜检查。用于硬皮病的早期诊断]
Rev Clin Esp. 1985 Jun;177(1):7-10.
9
Atypical Scleroderma-like Chronic GVHD in a Liver Transplant Patient, Clinical and MRI Correlations.肝移植患者非典型硬皮病样慢性移植物抗宿主病:临床与 MRI 的相关性。
Acta Dermatovenerol Croat. 2022 Sep;30(2):123-125.
10
Clinical and Histopathological Features of Scleroderma-like Disorders: An Update.硬皮病样疾病的临床和组织病理学特征:更新。
Medicina (Kaunas). 2021 Nov 20;57(11):1275. doi: 10.3390/medicina57111275.

引用本文的文献

1
Treatment Strategies for Cutaneous and Oral Mucosal Side Effects of Oncological Treatment in Breast Cancer: A Comprehensive Review.乳腺癌肿瘤治疗中皮肤及口腔黏膜副作用的治疗策略:一项综述
Biomedicines. 2025 Aug 4;13(8):1901. doi: 10.3390/biomedicines13081901.
2
Prevalence of Autoimmune Diseases in Patients Treated With Immune Checkpoint Inhibitors: An Epidemiological Study Using A Global Network of Health Care Organizations.接受免疫检查点抑制剂治疗患者的自身免疫性疾病患病率:一项利用全球医疗保健组织网络开展的流行病学研究
ACR Open Rheumatol. 2025 Jan;7(1):e11787. doi: 10.1002/acr2.11787.
3
Roles of gut microbiome-associated metabolites in pulmonary fibrosis by integrated analysis.
通过综合分析探讨肠道微生物群相关代谢产物在肺纤维化中的作用
NPJ Biofilms Microbiomes. 2024 Dec 19;10(1):154. doi: 10.1038/s41522-024-00631-4.
4
Scleroderma-like Lesions in a Patient Undergoing Combined Pembrolizumab and Routine Chemotherapy: A Case Report and Literature Review.接受帕博利珠单抗联合常规化疗的患者出现硬皮病样皮损:病例报告及文献复习。
Medicina (Kaunas). 2024 Jul 3;60(7):1092. doi: 10.3390/medicina60071092.
5
Skin Hypopigmentation in Hematology Disorders.血液系统疾病中的皮肤色素减退
Hematol Rep. 2024 Jun 4;16(2):354-366. doi: 10.3390/hematolrep16020036.
6
Scleroderma and scleroderma-like syndromes.硬皮病及硬皮病样综合征。
Front Immunol. 2024 Jun 3;15:1351675. doi: 10.3389/fimmu.2024.1351675. eCollection 2024.
7
Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.纳武利尤单抗致恶性黑色素瘤相关性系统性硬皮病。
In Vivo. 2024 May-Jun;38(3):1451-1453. doi: 10.21873/invivo.13589.
8
Morphoea induced by vaping.电子烟诱发的硬斑病。
Skin Health Dis. 2023 Sep 27;3(6):e279. doi: 10.1002/ski2.279. eCollection 2023 Dec.
9
Immune Checkpoint Inhibitors and Scleroderma: Data from the European Pharmacovigilance Database.免疫检查点抑制剂与硬皮病:来自欧洲药物警戒数据库的数据
Drugs Real World Outcomes. 2024 Mar;11(1):33-41. doi: 10.1007/s40801-023-00399-7. Epub 2023 Oct 31.
10
Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD-1-Induced Scleroderma.帕博利珠单抗继发硬皮病:一例报告及19例抗PD-1诱导的硬皮病病例回顾
Case Rep Oncol. 2023 Sep 6;16(1):846-856. doi: 10.1159/000533373. eCollection 2023 Jan-Dec.